Stock Performance and Market Context
On 31 Dec 2025, Symbiox Investment & Trading Co Ltd’s share price fell by 3.16%, closing at Rs.1.84, its lowest level in the past 52 weeks. This decline contrasts with the broader market’s positive momentum, as the Sensex opened 118.50 points higher and traded at 84,924.59, up 0.29%. The Sensex remains close to its 52-week high of 86,159.02, just 1.45% away, supported by bullish moving averages with the 50-day DMA above the 200-day DMA. Additionally, the BSE Small Cap index gained 0.79%, leading market advances, highlighting the relative weakness of Symbiox’s stock within its segment.
Symbiox’s stock has underperformed its sector by 4.02% today and is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward momentum and a lack of near-term price support.
Long-Term Price and Returns Analysis
Over the last 12 months, Symbiox Investment & Trading Co Ltd has delivered a negative return of 66.05%, a stark contrast to the Sensex’s positive 8.68% return over the same period. The stock’s 52-week high was Rs.6.02, underscoring the steep decline to its current level. This performance places the stock well below the broader market and its peers, reflecting persistent challenges in maintaining investor confidence and market valuation.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
See What's Driving the Rally →
Fundamental Metrics and Financial Health
Symbiox’s fundamental profile remains subdued, with a Mojo Score of 12.0 and a Mojo Grade of Strong Sell as of 13 Oct 2025, downgraded from Sell. The company’s market capitalisation grade stands at 4, indicating a relatively small market cap compared to larger NBFC peers. The stock’s long-term return on equity (ROE) averages a modest 0.85%, signalling limited profitability relative to shareholder equity.
Operating profit growth has been sluggish, with an annualised increase of just 5.22%, which is below expectations for a growth-oriented NBFC. The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) have been negative, adding to concerns about cash flow generation and operational efficiency. Over the past year, profits have declined by 31%, further weighing on the stock’s valuation and investor sentiment.
Relative Performance and Risk Assessment
Symbiox has underperformed the BSE500 index over multiple time frames, including the last three years, one year, and three months. This consistent underperformance highlights challenges in both the near and long term. The stock’s valuation appears risky when compared to its historical averages, reflecting market apprehension about its financial stability and growth prospects.
The majority of the company’s shares are held by non-institutional investors, which may contribute to lower liquidity and higher volatility in the stock price. This shareholder composition can affect market dynamics, especially during periods of price weakness.
Is Symbiox Investment & Trading Co Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Current Concerns
The stock’s recent decline to Rs.1.84 reflects a combination of factors including weak profitability metrics, negative EBITDA, and underwhelming growth rates. Its sustained trading below all major moving averages signals continued downward pressure. Despite a broadly positive market environment, Symbiox’s share price has not benefited from sector or market rallies, indicating company-specific challenges.
Investor caution is further underscored by the downgrade to a Strong Sell rating and the company’s low Mojo Score. The stock’s performance over the past year and longer term has been disappointing relative to benchmarks, with a significant erosion of shareholder value.
Market Environment and Sector Positioning
While the Sensex and small-cap indices have shown strength, Symbiox’s position within the NBFC sector remains subdued. The company’s market cap grade of 4 places it among smaller players, which may limit its ability to attract institutional interest or capital for expansion. The sector itself has seen mixed performances, but Symbiox’s relative underperformance highlights specific challenges faced by the company.
Overall, the stock’s 52-week low is a reflection of its financial and market standing as of late 2025, with limited signs of immediate recovery in price or fundamentals.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
